Organisation paid for research Program year 2022 Source: CMS Open Payments

Commonwealth Clinical Studies

Neither a doctor nor a teaching hospital

Research payments

$67,349

21 payments

Through program year 2022, Commonwealth Clinical Studies is reported as receiving $67,349 in research payments, across 21 payments.

By program year

2 rows
Year Kind Amount Payments
2022 Research $659 1
2019 Research $66,690 20

Breakdown

Who paid Research payments · program years 2019–2022
  1. Shire North American Group Inc $50,250 15 payments
  2. Pfizer Inc. $13,116 1 payment
  3. Allergan Inc. $2,103 2 payments
  4. AbbVie, Inc. $1,221 2 payments
  5. Intercept Pharmaceuticals, Inc. $659 1 payment
Studies the money was for Research payments · program years 2019–2022
  1. A Multicenter Openlabel Extension Study to Assess Longterm Safety of Pf00547659 in Subjects With Ulcerative Colitis Turandot II $13,116 1 payment
  2. A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis Aida $10,050 3 payments
  3. Study of the Effect of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies $10,050 3 payments
  4. Efficacy and Safety Study of Shp647 As Induction Therapy in Participants With Moderate to Severe Crohn's Disease $10,050 3 payments
  5. Efficacy and Safety of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Crohns Disease Carmen CD 307 $10,050 3 payments
  6. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302 $10,050 3 payments
  7. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $2,103 2 payments
  8. P11-282 $1,221 2 payments
  9. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $659 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record